Regeneron targets almost 50 patents in suit against Sandoz

Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

HLK adds CRISPR specialist as partner

UPC delivers first 'imminent infringement' decision in biosimilar dispute

AstraZeneca unit draws line under Samsung dispute

Regeneron targets almost 50 patents in suit against Sandoz

Editor's picks

Editor's picks

More features